🟢 AQST is trading 14% up today on a $150M refinancing and positive FDA feedback for Anaphylm

AQST is trading at $4.75 (+14%) as investors react to a $150 million refinancing deal and constructive FDA feedback regarding its Anaphylm treatment.

• The $150 million refinancing significantly improves balance-sheet flexibility and provides a de-risked financial roadmap for the company.
• Management highlighted positive regulatory momentum for Anaphylm following constructive discussions with the FDA.
• Sentiment remains strong as the company reaffirmed its 2026 revenue guidance, helping the stock outperform despite broader market weakness.